skip to main content
Centre for Health Economics and Policy Analysis
Feng Xie 2018

Feng Xie

Professor, Department of Health Research Methods, Evidence and Impact (HEI), McMaster University
Chair, Department Education Council
Department Education Coordinator
Member, Centre for Health Economics and Policy Analysis (CHEPA)

CRL 223
McMaster University
1280 Main Street West,
Hamilton, Ontario 
L8S 4M4

Feng Xie is a Professor of Health Economics in McMaster's Department of Health Research Methods, Evidence and Impact (HEI) and a member of CHEPA. His research interests include health technology assessment, economic evaluations using models and trial data, patient-reported outcome and preference measures, and health utility measures. Xie is deputy editor-in-chief of the BMC Journal: Health and Quality of Life Outcomes and an associated editor of Medical Decision Making. He received a Career Scientist Award from Ontario Ministry of Health and Long Term Care and a Canadian Institutes of Health Research (CIHR) New Investigator Award. Xie has been involved in numerous HTA and economic evaluations in assessing new health technologies to support national and provincial reimbursement decision-making. He is also interested in measuring patient-reported outcomes in the context of clinical trials and economic evaluations. He holds a PhD in pharmacoeconomics and outcomes research from the National University of Singapore; an MSc in pharmacy administration from Fudan University and a BSc in pharmacy from Shanghai Medical University.


  • Health technology assessment
  • Economic evaluations
  • Patient-reported outcome measures
  • Health utility measures
  • Patient value and preference


Xie F. Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation. Pharmacoeconomics. 2018. 36(8):883-888.

Chan KK, Xie F, Willan A, Pullenayegum E. Conducting EQ-5D Valuation Studies in Resource-Constrained Countries: The Potential Use of Shrinkage Estimators to Reduce Sample Size. Medical Decision Making. 2018.38(1):26-33. 

Xie F
, Pullenayegum E, Pickard AS, Ramos Goñi JM, Jo MW, Igarashi A. Transforming Latent Utilities to Health Utilities: East Does Not Meet West. Health Economics. 2017. 26(12):1524-1533.

Devji T, Levine O, Neupane B, Beyene J, Xie F. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMA Oncology. 2017. 3(3): 366-373. 

Xie F, Kovic B, Jin X, He X, Wang M, Silvestre C. Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies. Pharmacoeconomics. 2016. Nov. 34(11):1087-1100. 

Xie F, Pullenayegum EM, Gaebel K, Bansback N, Bryan S, Ohinmaa A, Poissant L, Johnson JA on behalf of Canadian EQ-5D-5L Valuation Study Group. A TTO-derived value set of the EQ-5D-5L for CanadaMedical Care. 2016.54(1):98-105.

Kovic B, Xie F.
 Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. Journal of Clinical Oncology. 2015. 33(20):2296-2302.


  • Health research methodology
  • Economic analysis of health care program
  • Advanced modeling methods
  • Health-related quality of life measures



All people
Please send questions, comments or suggestions to the Webmaster ( ).
Please review our Copyright Disclaimer policy

Interactive Marketing | Cubicle Fugitive